ALISO VIEJO, Calif.--(BUSINESS WIRE)--Clarient, Inc., a GE Healthcare company (NYSE:GE), and ACORN Research LLC announced today their strategic collaboration around molecular testing of tumor samples. The agreement will establish a standardized testing protocol across the ACORN network of oncology community practices and hospitals with treatment guidelines and clinical trial opportunities. These processes have the potential to improve oncology treatment and research that aim to deliver targeted treatments based on the specific genetic markers for each patient.
